Navigation Links
Heparin Antibodies May Put Patients At Risk

Patients developing antibodies to heparin, an anti-clotting drug, run the risk of either serious complications after undergoing a heart surgery, or death, according to a new research // . The Wake Forest University Baptist Medical Center’s professor of anesthesiology Thomas Slaughter said that the study aimed at finding out if an independent risk is posed by the development of heparin antibodies prior to the surgery.

Heparin is used in several procedures like heart catheterization or angioplasty, kidney dialysis, in addition to heart and vascular surgeries. Antibodies are developed in as many as 50% of the patients who are treated with heparin, the effect of which may even last for several months. The researchers are of the opinion that blood components are activated which cause inflammation and clotting in the case of subsequent treatment on patients who already carry heparin antibodies.

This will also lead to increased risks of strokes, heart rhythm problems, heart attacks, and other complications. The heparin antibody levels in the patients were studied by the researchers, before surgery, who came to the conclusion that the risk of hospitalization or death was twofold in the case of patients with the antibodies.

The Parsonnet risk score, a standardized risk scoring system was also used by the research scientists to ensure that the results of the study were not influenced by the baseline health status of the patients. The heparin antibodies were found in 13% of the patients who were to undergo surgery in the US.

Heparin can be easily be replaced by many other anti-clotting medications, but the Food and Drug Administration of the country will have to approve of them before they can be used. Patients may also postpone the surgery until the antibody levels in their bodies have subsided, which may at times take months together, and may not be practical if the patient concerned requires surgery immediately.


Page: 1

Related medicine news :

1. Complications In Kidney Failure Patients Linked To Heparin
2. Heparin does not protect from recurrent heart attacks
3. Heparin Based Nanoscale Materials Developed For Dialysis Treatment
4. Ordinary Heparin as Effective as Expensive Blood Thinner
5. Antibodies to fight HIV infection.
6. Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies
7. Scientists Develop Antibodies from Plant Seeds
8. Antibodies in Mother Affect Heart of Fetus
9. One in Three Heart Attack Patients Have No Chest Pains
10. Amphetamines Help Recovery of Stroke Patients
11. Painkillers Do Not Shorten Dying Patients Lives
Post Your Comments:

(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps ... provides a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
Breaking Medicine Technology: